Mansoor Abbas Qaisar, Muhammad Nadeem, Fateh Sher Chattah, Zarmina Roop, Muhammad Mujtaba Hashir, Bushra Iqbal.
Cinacalcet HCl for treatment of secondary hyperparathyroidism (SHPT) in hemodialysis patients: a single centre experience.
Pak J Med Health Sci Jan ;13(4):995-7.

Background: The use of Cinacalcet in hemodialysis patients to treat SHPT has recently been started in Pakistan. Cinacalcet can cause imbalance in Ca and PO4 homeostasis andK/DOQI guidelines suggest regular monitoring of iPTH, Ca and PO4 levels in dialysis patients especially those who are on cinacalcet . Aim : To determine the effectiveness of Cinacalcet treatment in SHPT. Methods: Total 34 SHP The modialysis patients were enrolled from dialysis unit of a tertiary care hospital in KSA. All patients received cinacalcet treatment; however three of them refused to continue because of persistent vomiting. The baseline and follow up data collected from 31 patients were analyzed. Results : The mean age of patients was 50±19 years; and frequency of males and females was 68% and 32%, respectively. Baseline mean iPTH level was decreased from 1068 to 841 pg/ml (p=0.041) with an overall 20.0% reduction rate; frequency of patients with iPTH levels (>600 pg/ml) was decreased (96.8 vs. 77.4%, p=0.041);and total 77.4% patients could achieve at least 30% reduction in baseline iPTH level. Mean PO4 level was decreased from 5.39 to 5.01 mg/dl (p=0.021); mean Albumin increased from 3.72 to 3.77 g/dl (p=0.754) Conclusion: Cinacalcet HCl therapy effectively treated secondary hyperparathyroidism in hemodialysis patients and maintained their serum iPTH, Ca and PO4 levels within target range.

PakMediNet -Pakistan's largest Database of Pakistani Medical Journals - http://www.pakmedinet.com